Literature DB >> 30983023

Should there be less emphasis on levodopa-induced dyskinesia in Parkinson's disease?

K Ray Chaudhuri1,2, Peter Jenner3, Angelo Antonini4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30983023     DOI： 10.1002/mds.27691

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  10 in total

1.  The movement disorder society nonmotor rating scale: Initial validation study.

Authors:  K Ray Chaudhuri; Anette Schrag; Daniel Weintraub; Alexandra Rizos; Carmen Rodriguez-Blazquez; Eugenia Mamikonyan; Pablo Martinez-Martin
Journal:  Mov Disord       Date:  2019-09-30       Impact factor: 10.338

2.  Evolution of Initial Pharmacologic Treatment of Newly Diagnosed Parkinson's Disease Patients over a Decade in Singapore.

Authors:  Shermyn Neo; Sheng Yong Aidan Wong; Hwee Lan Ng; Wei Li; Kay Yaw Tay; Wing Lok Au; Louis Chew Seng Tan
Journal:  Parkinsons Dis       Date:  2020-03-30

3.  Pallidal versus subthalamic nucleus deep brain stimulation for levodopa-induced dyskinesia.

Authors:  Shi-Ying Fan; Kai-Liang Wang; Wei Hu; Robert S Eisinger; Alexander Han; Chun-Lei Han; Qiao Wang; Shimabukuro Michitomo; Jian-Guo Zhang; Feng Wang; Adolfo Ramirez-Zamora; Fan-Gang Meng
Journal:  Ann Clin Transl Neurol       Date:  2019-12-08       Impact factor: 4.511

Review 4.  Rotigotine Transdermal Patch for Motor and Non-motor Parkinson's Disease: A Review of 12 Years' Clinical Experience.

Authors:  Vanessa Raeder; Iro Boura; Valentina Leta; Peter Jenner; Heinz Reichmann; Claudia Trenkwalder; Lisa Klingelhoefer; K Ray Chaudhuri
Journal:  CNS Drugs       Date:  2021-02-09       Impact factor: 5.749

5.  Impact of disease stage and age at Parkinson's onset on patients' primary concerns: Insights for targeted management.

Authors:  Roongroj Bhidayasiri; Thanatat Boonmongkol; Yuwadee Thongchuam; Saisamorn Phumphid; Nitinan Kantachadvanich; Pattamon Panyakaew; Priya Jagota; Rachaneewan Plengsri; Marisa Chokpatcharavate; Onanong Phokaewvarangkul
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

6.  Amantadine ER (Gocovri®) Significantly Increases ON Time Without Any Dyskinesia: Pooled Analyses From Pivotal Trials in Parkinson's Disease.

Authors:  Robert A Hauser; Ryan R Walsh; Rajesh Pahwa; Dustin Chernick; Andrea E Formella
Journal:  Front Neurol       Date:  2021-03-26       Impact factor: 4.003

7.  Opicapone as an Add-on to Levodopa in Patients with Parkinson's Disease Without Motor Fluctuations: Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial.

Authors:  Joaquim J Ferreira; Werner Poewe; Olivier Rascol; Fabrizio Stocchi; Angelo Antonini; Joana Moreira; Ana Pereira; José-Francisco Rocha; Patrício Soares-da-Silva
Journal:  Neurol Ther       Date:  2022-06-16

8.  Retrospective Multicenter Study on Outcome Measurement for Dyskinesia Improvement in Parkinson's Disease Patients with Pallidal and Subthalamic Nucleus Deep Brain Stimulation.

Authors:  Fangang Meng; Shanshan Cen; Zhiqiang Yi; Weiguo Li; Guoen Cai; Feng Wang; Stephan S Quintin; Grace E Hey; Jairo S Hernandez; Chunlei Han; Shiying Fan; Yuan Gao; Zimu Song; Junfei Yi; Kailiang Wang; Liangwen Zhang; Adolfo Ramirez-Zamora; Jianguo Zhang
Journal:  Brain Sci       Date:  2022-08-09

9.  Genomic Analysis Identifies New Loci Associated With Motor Complications in Parkinson's Disease.

Authors:  Ho-Sung Ryu; Kye Won Park; Nari Choi; Jinhee Kim; Young-Min Park; Sungyang Jo; Mi-Jung Kim; Young Jin Kim; Juyeon Kim; Kiju Kim; Seong-Beom Koh; Sun Ju Chung
Journal:  Front Neurol       Date:  2020-07-07       Impact factor: 4.003

Review 10.  Medical Management and Prevention of Motor Complications in Parkinson's Disease.

Authors:  Stephen D Aradi; Robert A Hauser
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.